miR-214 promotes osteoclastogenesis by targeting pten/pi3k/Akt pathway

RNA Biology

Volumn 12, Issue 3, 2015, Pages 343-353

  Zhao, Chenyang ^a,b,d   Sun, Weijia ^a,b   Zhang, Pengfei ^a,b   Ling, Shukuan ^b   Li, Yuheng ^b   Zhao, Dingsheng ^b   Peng, Jiang ^c   Wang, Aiyuan ^c   Li, Qi ^b   Song, Jinping ^b   Wang, Cheng ^c   Xu, Xiaolong ^c   Xu, Zi ^a,b   Zhong, Guohui ^b   Han, Bingxing ^b   Chang, Yan Zhong ^a   Li, Yingxian ^b  

^a HEBEI NORMAL UNIVERSITY   (China)

^b China Astronaut Research and Training Center   (China)

^c Chinese Peoples Liberation Army General Hospital   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

MiRNA; Osteoclast; Osteoporosis; PI 3 kinase; PTEN

Indexed keywords

COLONY STIMULATING FACTOR 1; GELATINASE B; MICRORNA 214; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN ACP5; PROTEIN CLCN7; PROTEIN CTSK; PROTEIN KINASE B; UNCLASSIFIED DRUG; MICRORNA; MIRN214 MICRORNA, MOUSE; OLIGONUCLEOTIDE; PTEN PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; UPREGULATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; BOVINE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; MONOCYTE; NUCLEOTIDE SEQUENCE; OSTEOPOROSIS; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

MUS MUSCULUS; VERTEBRATA;

ANIMALS; BASE SEQUENCE; BONE DENSITY; BONE MARROW CELLS; CATTLE; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, TRANSGENIC; MICRORNAS; MOLECULAR SEQUENCE DATA; MONOCYTES; OLIGONUCLEOTIDES; OSTEOCLASTS; OSTEOPOROSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84928230801     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.1080/15476286.2015.1017205     Document Type: Article

References (45)

1. Del Fattore A, Teti A, Rucci N. Osteoclast receptors and signaling. Arch Biochem Biophys 2008; 473:147–60; http://dx.doi.org/10.1016/j.abb.2008.01.011.
2. Ross FP, Teitelbaum SL. Alphavbeta3 and macrophage colony-stimulating factor: Partners in osteoclast biology. Immunol Rev 2005; 208:88–105; PMID:16313343; http://dx.doi.org/10.1111/j.0105-2896.2005.00331.x.
3. Miyazaki T, Tanaka S, Sanjay A, Baron R. The role of c-Src kinase in the regulation of osteoclast function. Mod Rheumatol 2006; 16: 68–74; PMID:16633924;http://dx.doi.org/10.3109/s10165-006-0460-z.
4. Edwards CM Mundy GR. Eph receptors and ephrin signaling pathways: A role in bone homeostasis. Int J Med Sci 2008; 5:263–72; PMID:18797510; http://dx.doi.org/10.7150/ijms.5.263.
5. Hattersley G, Owens J, Flanagan AM, Chambers TJ. Macrophage colony stimulating factor (M-CSF) is essential for osteoclast formation in vitro. Biochem Biophys Res Commun 1991; 177:526–31; PMID:2043138; http://dx.doi.org/10.1016/0006-291X(91)92015-C.
6. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/ TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256:449–55; PMID:10080918; http://dx.doi.org/10.1006/bbrc.1999.0252.
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95:3597–602; PMID:9520411; http://dx.doi.org/10.1073/pnas.95.7.3597.
8. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3:889–901; PMID:12479813; http://dx.doi.org/10.1016/S1534-5807(02)00369-6.
9. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004; 279:45969–79; PMID:15304486; http://dx.doi.org/10.1074/jbc.M408795200.
10. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 2005; 280:32905–13; PMID:16046394; http://dx.doi.org/10.1074/jbc.M505820200.
11. Bartel DP MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116:281–97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5.
12. Kapinas K, Delany AM. MicroRNA biogenesis and regulation of bone remodeling. Arthritis Res Ther 2011; 13:220; PMID:21635717; http://dx.doi.org/10.1186/ar3325.
13. Zhao H, Ito Y, Chappel J, Andrews NW, Teitelbaum SL, Ross FP. Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Dev Cell 2008; 14:914–25; PMID:18539119; http://dx.doi.org/10.1016/j.devcel.2008.03.022.
14. Wang J, Guan X, Guo F, Zhou J, Chang A, Sun B, Cai Y, Ma Z, Dai C, Li X, et al. miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptorrelated protein 6. Cell Death Dis 2013; 4:e845; PMID:24113179; http://dx.doi.org/10.1038/cddis.2013.356.
15. Hassan MQ, Maeda Y, Taipaleenmaki H, Zhang W, Jafferji M, Gordon JA, Li Z, Croce CM, van Wijnen AJ, Stein JL, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem 2012; 287:42084–92; PMID:23060446; http://dx.doi.org/10.1074/jbc.M112.377515.
16. Zhang JF, Fu WM, He ML, Wang H, Wang WM, Yu SC, Bian XW, Zhou J, Lin MC, Lu G, et al. MiR-637 maintains the balance between adipocytes and osteoblasts by directly targeting Osterix. Mol Biol Cell 2011; 22:3955–61; PMID:21880893; http://dx.doi.org/10.1091/mbc.E11-04-0356.
17. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010; 285:25221–31; PMID:20551325; http://dx.doi.org/10.1074/jbc.M110.116137.
18. Kapinas K, Kessler CB, Delany AM. miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling. J Cell Biochem 2009; 108:216–24; PMID:19565563; http://dx.doi.org/10.1002/jcb.22243.
19. Wang X, Guo B, Li Q, Peng J, Yang Z, Wang A, Li D, Hou Z, Lv K, Kan G, et al. miR-214 targets ATF4 to inhibit bone formation. Nat Med 2013; 19:93–100; PMID:23223004; http://dx.doi.org/10.1038/nm.3026.
20. Watanabe T, Sato T, Amano T, Kawamura Y, Kawamura N, Kawaguchi H, Yamashita N, Kurihara H, Nakaoka T. Dnm3os, a non-coding RNA, is required for normal growth and skeletal development in mice. Dev Dyn 2008; 237:3738–48; PMID:18985749; http://dx.doi.org/10.1002/dvdy.21787.
21. Ishibashi O, Niwa S, Kadoyama K, Inui T. MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 2006; 79:1657–60; PMID:16806280; http://dx.doi.org/10.1016/j.lfs.2006.05.024.
22. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001; 104:205–15; PMID:11207362; http://dx.doi.org/10.1016/S0092-8674(01)00206-9.
23. Gowen M, Lazner F, Dodds R, Kapadia R, Feild J, Tavaria M, Bertoncello I, Drake F, Zavarselk S, Tellis I, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999; 14:1654–63; PMID:10491212; http://dx.doi.org/10.1359/jbmr.1999.14.10.1654.
24. Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 2005; 36:159–72; PMID:15664014; http://dx.doi.org/10.1016/j.bone.2004.09.020.
25. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998; 95:13453–8; PMID:9811821; http://dx.doi.org/10.1073/pnas.95.23.13453.
26. Li LM, Hou DX, Guo YL, Yang JW, Liu Y, Zhang CY, Zen K. Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product- induced apoptosis delay in monocytes. J Immunol 2011; 186:2552–2560; PMID:21228352; http://dx.doi.org/10.4049/jimmunol.1001633.
27. Jindra PT, Bagley J, Godwin JG, Iacomini J. Costimulation- dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting pten. J Immunol 2010; 185:990–997; PMID:20548023; http://dx.doi.org/10.4049/jimmunol.1000793.
28. Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68:425–433; PMID:18199536; http://dx.doi.org/10.1158/0008-5472.CAN-07-2488.
29. Sugatani T. PTEN regulates RANKL- and osteopontin- stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem 2002; 278:5001–5008; PMID:12460992; http://dx.doi.org/10.1074/jbc.M209299200.
30. Reddy SV, Scarcez T, Windle JJ, Leach RJ, Hundley JE, Chirgwin JM, Chou JY, Roodman GD. Cloning and characterization of the 50-flanking region of the mouse tartrate-resistant acid phosphatase gene. J Bone Miner Res 1993; 8:1263–70; PMID:8256664; http://dx.doi.org/10.1002/jbmr.5650081015.
31. Sugatani T, Vacher J, Hruska KA. A microRNA expression signature of osteoclastogenesis. Blood 2011; 117:3648–57; PMID:21273303; http://dx.doi.org/10.1182/blood-2010-10-311415.
32. Sugatani T, Hruska KA. MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem 2007; 101:996–9; PMID:17471500; http://dx.doi.org/10.1002/jcb.21335.
33. Mann M, Barad O, Agami R, Geiger B, Hornstein E. miRNA-based mechanism for the commitment of multipotent progenitors to a single cellular fate. Proc Natl Acad Sci U S A 2010; 107:15804–9; PMID:20720163; http://dx.doi.org/10.1073/pnas.0915022107.
34. Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 2011; 63:1582–90; PMID:21425254; http://dx.doi.org/10.1002/art.30321.
35. Kagiya T, Nakamura S. Expression profiling of micro-RNAs in RAW264.7 cells treated with a combination of tumor necrosis factor a and RANKL during osteoclast differentiation. J Periodontal Res 2013; 48:373–85; PMID:23078176; http://dx.doi.org/10.1111/jre.12017.
36. Cheng P, Chen C, He HB, Hu R, Zhou HD, Xie H, Zhu W, Dai RC, Wu XP, Liao EY, et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J Bone Miner Res 2013; 28:1180–90; PMID:23225151;http://dx.doi.org/10.1002/jbmr.1845.
37. Cheng P, Chen C, He H-B, Hu R, Zhou H-D, Xie H, Zhu W, Dai R-C, Wu X-P, Liao E-Y, et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. J Bone Miner Res 2013; 28:1180–1190; PMID:23225151; http://dx.doi.org/10.1002/jbmr.1845.
38. Desvignes T, Contreras A, Postlethwait JH. Evolution of the miR199-214 cluster and vertebrate skeletal development. RNA Biol 2014; 11:281–94; PMID:24643020; http://dx.doi.org/10.4161/rna.28141.
39. Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68:425–33; PMID:18199536; http://dx.doi.org/10.1158/0008-5472.CAN-07-2488.
40. Jindra PT, Bagley J, Godwin JG, Iacomini J. Costimulation- dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. J Immunol 2010; 185:990–7; PMID:20548023; http://dx.doi.org/10.4049/jimmunol.1000793.
41. Cao X Targeting osteoclast-osteoblast communication. Nat Med 2011; 17:1344–6; PMID:22064408; http://dx.doi.org/10.1038/nm.2499.
42. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008; 473:201–9; PMID:18406338; http://dx.doi.org/10.1016/j.abb.2008.03.027.
43. van Balkom BW, de Jong OG, Smits M, Brummelman J, den Ouden K, de Bree PM, van Eijndhoven MA, Pegtel DM, Stoorvogel W, Wurdinger T, et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood 2013; 121:3997–4006, S1-15; http://dx.doi.org/10.1182/blood-2013-02-478925.
44. Chen L, Charrier A, Zhou Y, Chen R, Yu B, Agarwal K, Tsukamoto H, Lee LJ, Paulaitis ME, Brigstock DR. Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 2014; 59:1118–29; PMID:24122827; http://dx.doi.org/10.1002/hep.26768.
45. Iwaniec UT, Wronski TJ, Liu J, Rivera MF, Arzaga RR, Hansen G, Brommage R. PTH stimulates bone formation in mice deficient in Lrp5. J Bone Miner Res 2007; 22:394–402; PMID:17147489; http://dx.doi.org/10.1359/jbmr.061118.